美国 BioSante Pharmaceuticals 
美国BioSante制药公司（BPA）
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's key products are LibiGel® (testosterone gel) in Phase III clinical development under an SPA, to treat female sexual dysfunction, and Elestrin™ (estradiol gel), FDA approved to treat hot flashes in menopausal women. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding $2.0 - $4.0 billion, and the current market for hormonal contraception is approximately $3.0 billion.

The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery systems and aesthetic medicine (BioLook™).

On June 30th, 2009, BioSante announced entering into a definitive merger agreement with Cell Genesys (CEGE) in an all-stock transaction, with BioSante as the surviving company.

The merged company will focus primarily on LibiGel, BioSante's testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD). The merged company will also seek future development opportunities for Cell Genesys' GVAX Immunotherapies including potential combination with BioVant™, BioSante's vaccine adjuvant, as well as possible external collaborations, and will also seek to outlicense other Cell Genesys technologies.

Upon completion of the transaction, BioSante stockholders prior to the merger are expected to own approximately 60.4 percent of the outstanding shares of the combined company and the former Cell Genesys stockholders are expected to own 39.6 percent. On June 23, 2009 Cell Genesys had $36 million in cash.